Arkolith/Insider Trading/XENE/Form 4

DiFabio Andrea

Chief Legal OfficerXenon Pharmaceuticals Inc. (XENE) · full profile →Form 4 · filed Mar 11, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$157K
Net Open-Market Flow
-$157K
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 10, 2026Sell(S)3K$60.11$157K5K
Mar 9, 2026Option exercise(M)8K——8K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 9, 2026Option exercise(M)8K—$00
Mar 9, 2026Grant(A)8K—$08K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-102667) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML